1. Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells
- Author
-
Silene Migliorini, Luziane Potrich Bellé, Renata Chaves Albuquerque, Felipe Augusto Dörr, Ana Campa, Edson Mendes de Oliveira, Irene S. Soares, Sabrina Sayori Okada, Melissa Cavalheiro Tourino, and Franciele Hinterholz Knebel
- Subjects
Tryptamine ,Kynurenine pathway ,Clinical Biochemistry ,Dimethyltryptamine ,Cell Biology ,General Medicine ,Pharmacology ,Biology ,Biochemistry ,Peripheral blood mononuclear cell ,Immune tolerance ,chemistry.chemical_compound ,chemistry ,Serotonin ,Indoleamine 2,3-dioxygenase ,Kynurenine - Abstract
Indoleamine 2,3-dioxygenase (IDO) is an interferon-γ (IFN-γ)-induced tryptophan-degrading enzyme, producing kynurenine (KYN) that participates in the mechanism of tumor immune tolerance. Thus, IDO inhibition has been considered a strategy for anticancer therapy. The aim of this study was to identify whether the metabolites originated from the competitive routes of tryptophan metabolism, such as the serotonergic or N, N-dimethyltryptamine (DMT) pathways, have inhibitory effects on recombinant human IDO (rhIDO) activity. Serotonin and melatonin had no effect; on the other hand, tryptamine (TRY) and DMT modulated the activity of rhIDO as classical non-competitive inhibitors, with Ki values of 156 and 506 μM, respectively. This inhibitory effect was also observed on constitutively expressed or IFN-γ-induced IDO in the A172 human glioma cell line. TRY and DMT increased the cytotoxic activity of peripheral blood mononuclear cells (PBMCs) in co-culture assays. We conclude that the IDO inhibition by TRY and DMT contributed to a more effective tumor-reactive response by the PBMCs.
- Published
- 2013
- Full Text
- View/download PDF